Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

NCT00287222 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT00287222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00287222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Lead sponsor
University of Arkansas
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
September 30, 2010
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma